Abstract
Benign Cutaneous Lymphoid Hyperplasia (CLH) is a B-cell pseudolymphoma of an unknown origin. The face is the most affected site in CLH. This report presents the cases of 3 patients with CLH who were treated with rituximab. It is a hypothesis that rituximab is useful for treating resistant-to-relapsing forms of CLH that do not respond to previous therapies but must be checked with appropriate designs research.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.